Ontology highlight
ABSTRACT:
SUBMITTER: An HJ
PROVIDER: S-EPMC6718427 | biostudies-literature | 2019 Sep
REPOSITORIES: biostudies-literature
Scientific reports 20190902 1
Recently, ramucirumab, a drug that targets vascular endothelial growth factor receptor (VEGFR), was clinically approved; therefore, we evaluated VEGFR2 expression and its predictive roles in tumor progression in clear cell renal cell carcinoma (CCRCC). Since we do not have many options for treating aggressive renal cell carcinoma patients, the application of anti-VEGFR2 therapy might be useful. Myoferlin (MYOF) is a 230 kDa transmembrane multi-C2-domain protein that contributes to plasma membran ...[more]